Cool-Bio

Cool-Bio is a private pre-clinical biopharmaceutical company developing hypothermia-activated biologics designed to work under controlled cooling conditions. Its technology aims to create therapeutics that can be turned on or off with body temperature, with an initial focus on cardiovascular and acute care settings where therapeutic hypothermia is already used. The company’s lead program has been described as a cold-activated anti-platelet antibody intended to reduce bleeding complications associated with cardiac surgery. Cool-Bio appears to be a small, venture-backed company founded around 2011 and based in the greater Philadelphia/Wayne, Pennsylvania area. Public information on its pipeline and corporate operations is limited, suggesting it remains an early-stage private company.